Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study.

被引：3
|
作者：
Powles, Thomas
Albiges, Laurence
Jalkanen, Katriina Johanna
De Velasco, Guillermo
Burotto, Mauricio
Ghatalia, Pooja
Suarez, Cristina
Lam, Elaine T.
Iacovelli, Roberto
Gumus, Mahmut
Verzoni, Elena
Kollmannsberger, Christian K.
Stadler, Walter Michael
Venugopal, Balaji
Shinde, Reshma
Saretsky, Todd L.
He, Li
Vickery, Donna
Choueiri, Toni K.
Rini, Brian I.
机构：
[1] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, London, England
[2] Univ Paris Saclay, Gustave Roussy, Paris, France
[3] Helsinki Univ Hosp, Helsinki, Finland
[4] 12 Octubre Univ Hosp, Med Oncol Dept, Madrid, Spain
[5] Bradford Hill Clin Res Ctr, Santiago, Chile
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Hosp Univ Vall dHebron, Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[8] Univ Colorado, Canc Ctr, Aurora, CO USA
[9] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy
[10] Istanbul Medeniyet Univ, Goztepe Prof Dr Suleyman Yalcin City Hosp, Istanbul, Turkiye
[11] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[12] BC Canc Vancouver Canc Ctr, Vancouver, BC, Canada
[13] Univ Chicago, Chicago, IL USA
[14] Univ Glasgow, Beatson West Scotland Canc Ctr, Glasgow, Scotland
[15] Merck & Co Inc, Rahway, NJ USA
[16] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[17] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2024.42.4_suppl.361
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
361
引用
收藏
页码：361 / 361
页数：1
相关论文
共 50 条
  • [1] Final analysis of the phase III LITESPARK-005 study of belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC)
    Rini, B. I.
    Rodriguez, C. Suarez
    Albiges, L.
    Jalkanen, K.
    Oria, G. A. De Velasco
    Burotto, M.
    Ghatalia, P.
    Iacovelli, R.
    Lam, E. T.
    Verzoni, E.
    Gumus, M.
    Stadler, W.
    Kollmannsberger, C. K.
    Melichar, B.
    Venugopal, B.
    Lin, J.
    Perini, R.
    Vickery, D.
    Choueiri, T. K.
    Powles, T. B.
    ANNALS OF ONCOLOGY, 2024, 35 : 1262 - 1263
  • [2] Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma: Subgroup analysis of the phase 3 LITESPARK-005 study
    Albiges, Laurence
    Choueiri, Toni K.
    Peltola, Katriina
    de Velasco, Guillermo
    Burotto, Mauricio
    Suarez, Cristina
    Ghatalia, Pooja
    Iacovelli, Roberto
    Lam, Elaine T.
    Verzoni, Elena
    Gumus, Mahmut
    Stadler, Walter M.
    Kollmannsberger, Christian
    Melichar, Bohuslav
    Venugopal, Balaji
    Xing, Aiwen
    Perini, Rodolfo F.
    Vickery, Donna
    Rini, Brian
    Powles, Thomas
    ONCOLOGIST, 2024, 29 : S3 - S4
  • [3] Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): Randomized open-label phase III LITESPARK-005 study
    Albiges, L.
    Rini, B. I.
    Peltola, K.
    Oria, G. A. De Velasco
    Burotto, M.
    Rodriguez, C. Suarez
    Ghatalia, P.
    Iacovelli, R.
    Lam, E. T.
    Verzoni, E.
    Gumus, M.
    Stadler, W. M.
    Kollmannsberger, C. K.
    Melichar, B.
    Venugopal, B.
    Wang, A.
    Perini, R.
    Vickery, D.
    Powles, T. B.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1329 - S1330
  • [4] Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.
    Albiges, Laurence
    Powles, Thomas
    Suarez, Cristina
    Jalkanen, Katriina Johanna
    Burotto, Mauricio
    Ghatalia, Pooja
    Iacovelli, Roberto
    Lam, Elaine T.
    Verzoni, Elena
    Gumus, Mahmut
    Stadler, Walter Michael
    Kollmannsberger, Christian K.
    Melichar, Bohuslav
    Venugopal, Balaji
    Lin, Jingyi
    Perini, Rodolfo F.
    Vickery, Donna
    Rini, Brian I.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 538 - 538
  • [5] Belzutifan versus everolimus for previously treated advanced clear cell renal cell carcinoma (ccRCC): Updated follow-up of the East Asian subgroup of the randomized phase III LITESPARK-005 trial
    Lee, J-L.
    Park, S. H.
    Kato, T.
    Saika, T.
    Masumori, N.
    Oya, M.
    Nishimoto, K.
    Fujimoto, H.
    Eto, M.
    Kishida, T.
    Lee, H. J.
    Su, Y-L.
    Miura, Y.
    Matsubara, N.
    Kitamura, H.
    Cheng, A. C. K.
    Xing, A.
    Perini, R.
    Vickery, D.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2024, 35 : S1505 - S1505
  • [6] Phase II study of belzutifan plus cabozantinib for previously treated advanced renal cell carcinoma (RCC): Update from cohort 2 of LITESPARK-003
    McDermott, D. F.
    Choueiri, T. K.
    Tykodi, S.
    Merchan, J.
    Roy, A.
    Perini, R.
    Vickery, D.
    Bauer, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1208 - +
  • [7] LITESPARK-024: A randomized phase 1/2 study of belzutifan with or without palbociclib for previously treated advanced renal cell carcinoma
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    ONCOLOGIST, 2023, 28 : S11 - S11
  • [8] The randomized phase 1/2 LITESPARK-024 study of belzutifan with or without palbociclib in patients with advanced renal cell carcinoma (RCC)
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    CANCER RESEARCH, 2023, 83 (08)
  • [9] LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).
    McDermott, David F.
    Peer, Avivit
    Agarwal, Neeraj
    Atkins, Michael B.
    Cornell, Jerry
    Perini, Rodolfo F.
    Grossmann, Kenneth F.
    Gurney, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] METEOR: results from the randomized phase 3 trial of cabozantinib versus everolimus in pts with advanced renal cell carcinoma (RCC)
    Powles, Thomas
    Escudier, Bernard
    Mainwaring, Paul N.
    Rini, Brian I.
    Donskov, Frede
    Hammers, Hans J.
    Hutson, Thomas E.
    Roth, Bruce
    Peltola, Katriina
    Lee, Jae Lyun
    Heng, Daniel Y. C.
    Schmidinger, Manuela
    Borgman, Anne
    Hessel, Colin
    Scheffold, Christian
    Schwab, Gisela
    Tannir, Nizar M.
    Motzer, Robert J.
    Choueiri, Toni K.
    BJU INTERNATIONAL, 2015, 116 : 19 - 19
12345